• 關於安成About Us
    • Company Profile
    • Management Team
    • Milestones
    • Plant & Quality
    • Join Us
    • Contact
  • Products
  • 研究與發展Research & Development
    • High Barrier Generics
  • 投資人關係
    • Shareholder Services
    • Corporate Governance
    • Unaudited Monthly Sales
    • Financial Report
    • Shareholder Contacts
  • 新聞發佈News & Media
    • News
    • Announcement

News

Announcement

Home > News & Media > News
Communication starts here.
2022.04
TWi’ ANDA for Fluphenazine HCl Tablets (equivalent to Prolixin®) has been officially approved by US FDA
2022.03
TWi officially launches its Mycophenolic Acid Delayed-Release Tablets in TWi label
2021-01
TWi officially launches generic Dimethyl Fumarate DR Capsules in TWi label
2020-10
TWi’ ANDA for Dimethyl Fumarate DR Capsules (equivalent to Tecfidera®) has been officially approved by US FDA
2020.08
TWi officially launches generic Propafenone HCl ER Capsules in TWi label
2020.07
TWi officially launches generic Terbutaline Sulfate Tablets in TWi label
2020.07
TWi successfully launches generic Fenofibric Acid DR Capsules in TWi label
2020.06
TWi's ANDA for Terbutaline Sulfate Tablets (equivalent to Brethine®) has been officially approved by US FDA
2020.06
TWi's ANDA for Propafenone HCl ER Capsules (equivalent to Rythmol SR®) has been officially approved by US FDA
2020.03
TWi successfully launches generic Testosterone Gel 1.62% Pump CIII in TWi label

 

Pages:1 - 2 - 3 - 4 - 5 - 6 - 7« Pre · Next »

©Copyright 2013 安成國際藥業股份有限公司版權所有